accountPrexton Licenses Domain's Parkinson's Disease Drug Genetic Engineering News Domain Therapeutics granted Prexton Therapeutics, a spin-off company of Merck Serono, an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson's disease. and more ยป...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Prexton Licenses Domain's Parkinson's Disease Drug - Genetic Engineering News
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account